Featured Research

from universities, journals, and other organizations

Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss

Date:
March 2, 2009
Source:
Journal of Clinical Investigation
Summary:
A new report describes the development of a cell-permeable inhibitor that specifically blocks the contribution of the protein RANK to the formation and function of the cells responsible for breaking down bone. Importantly, this drug protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion that this approach might be beneficial to individuals with diseases such as osteoporosis.

A new report describes the development of a cell-permeable inhibitor that specifically blocks the contribution of the protein RANK to the formation and function of the cells responsible for breaking down bone.

Importantly, this drug protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion that this approach might be beneficial to individuals with diseases such as osteoporosis.

Soo Young Lee and colleagues, at Ewha Womans University, Republic of Korea, have developed a cell-permeable inhibitor of the mouse protein RANK (which they termed RRI) that is likely to aid in the development of selective drugs to treat diseases that involve substantial bone loss, for example, osteoporosis, periodontitis, and arthritis.

Central to understanding diseases that involve substantial loss of bone density, and thereby loss of bone strength, is insight into the molecules that regulate the formation and function of the cells that slowly breakdown bone, cells known as osteoclasts.

One molecule known to regulate both these processes is RANK, however, its utility as a target for drugs that prevent bone destruction might to be limited, as it is involved in many other biological functions.

The authors designed RRI to target a region of RANK that they recently found to be specific for the formation of osteoclasts. RRI was found to inhibit in vitro RANKL-induced formation of mouse osteoclasts and in vitro osteoclast-mediated bone destruction. More importantly, it protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion similar drugs might be beneficial to individuals with diseases that involve bone destruction, such as osteoporosis.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kim et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI36809

Cite This Page:

Journal of Clinical Investigation. "Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss." ScienceDaily. ScienceDaily, 2 March 2009. <www.sciencedaily.com/releases/2009/03/090302183120.htm>.
Journal of Clinical Investigation. (2009, March 2). Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2009/03/090302183120.htm
Journal of Clinical Investigation. "Getting Down To Specifics: Blocking One RANK Function Inhibits Bone Loss." ScienceDaily. www.sciencedaily.com/releases/2009/03/090302183120.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins